Antiandrogens for COVID-19: real-time meta analysis of 49 studies

• Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies from 24 independent teams in 12 different countries show statistically significant improvements in isolation (17 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 30% [21‑38%] improvement. Results are better for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies. • Results are robust — in exclusion sensitivity analysis 24 of 49 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.• This analysis combines the results of several different antiandrogens. Results for individual treatments may vary. • No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 18% of antiandrogen studies show zero events with treatment. • All data to reproduce this paper and sources are in the appendix. Other meta analyses for antiandrogen can be found in [Cheema, Kotani], showing significant improvements for mortality, hospitalization, recovery, and progression.

Percentage improvement with antiandrogen (more)

	All studies	Early treatment	Late treatment	Studies	Patients	Authors
All studies	30% [21‑38%]****	44% [31‑55%]****	64% [46‑75%]****	49	119,838	533
Randomized Controlled TrialsRCTs	58% [37‑73%]****	64% [26‑82%]**	58% [32‑74%]***	18	2,942	220
Mortality	38% [22‑51%]****	39% [29‑48%]****	63% [45‑76%]****	33	113,013	370
HospitalizationHosp.	30% [9‑47%]**	81% [46‑93%]**	21% [-10‑43%]	15	8,854	218
RCT mortality	63% [46‑75%]****	71% [-75‑95%]	62% [41‑75%]****	14	2,630	161